Pfizer (PFE, Financial) is stepping up its obesity drug development by naming James List as its new chief internal medicine officer, according to a Friday press release. The former Johnson & Johnson (JNJ, Financial) executive brings extensive expertise from his post?doctoral research in GLP?1 weight loss drugs.
Based in New York, the pharmaceutical giant is refocusing its R&D efforts to fast?track development of cardiovascular, metabolic, hematologic, and obesity treatments. List previously led global therapeutic initiatives at J&J's Janssen unit, emphasizing his background in managing complex drug portfolios.
The move comes as Pfizer intensifies competition in the obesity market, currently dominated by Eli Lilly (LLY, Financial) and Novo Nordisk (NVO, Financial). A recent TD Cowen note indicated that the duopoly is expected to persist until 2030. In 2023, Pfizer discontinued its twice?daily oral obesity regimen due to adverse side effects, shifting attention toward a once?daily formulation now in late?stage development.
The appointment is part of Pfizer's broader strategy to enhance its anti?obesity portfolio and secure a stronger global market presence.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。